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1  | INTRODUC TION
Medication- related osteonecrosis of the jaw (MRONJ) has been 
defined by the American Association of Oral and Maxillofacial 
Surgeons as an exposure of necrotic bone in the oral cavity, or bone 
that can be probed through an intraoral or extraoral fistula(e) of long 
lasting duration (within eight weeks after clinical identification) in 
a patient currently taking or previously treated with antiresorptive 
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Abstract
Objective: In the recent years, an increasing number of peri- implant medication- 
related osteonecrosis of the jaw (PI- MRONJ) have been reported in literature, both 
in oncologic and osteoporotic patients. The aim of this study is to describe 19 cases 
of patients previously diagnosed as affected by peri- implantitis, who were treated for 
PI- MRONJ, with consideration on clinical and histopathological features.
Materials and Methods: Patients included were affected by postmenopausal os-
teoporosis and were administered with different antiresorptive drugs. Due to the 
presence of clinical and radiological signs of peri- implantitis not healed after non- 
surgical periodontal treatment, they were referred to the Complex Operating Unit of 
Odontostomatology of the University of Bari. Then, after a drug holiday of at least 
3 months and cycles of antibiotics, and after other cycles of periodontal treatment, 
patients underwent the surgical removal of implant fixtures and surrounding bone.
Results: Although the previous diagnosis of peri- implantitis, the histopathological 
analysis with both conventional and confocal laser scanner microscopy confirmed 
the diagnosis of peri- implantitis- like MRONJ.
Conclusion: Peri- implantitis not healed after conventional treatment in patients at 
risk on MRONJ occurrence should be considered as peri- implantitis- like PI- MRONJ 
and treated as required in order to get complete healing of the pathological condition, 
thus avoiding delay in the diagnosis.
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or antiangiogenic drugs but never undergone radiotherapy for head 
and neck neoplasms (Ruggiero et al., 2014).
At the beginning, only bisphosphonates (BPs) administered in pa-
tients affected by bone metastases of solid tumours or osteoporosis 
were considered involved in MRONJ occurrence; nowadays, many 
other drugs have been described in the English literature as related 
to MRONJ, such as Denosumab (Favia et al., 2016), Bevacizumab 
(Antonuzzo et al., 2017), Adalimumab (Cassoni et al., 2016), Infliximab 
(Favia et al., 2017) and Lenvatinib (Mauceri et al., 2019) prescribed 
even for rheumatic disorders (rheumatoid arthritis, Crohn's diseases 
and ulcerative colitis).
Peri- implantitis is considered the major biological complication 
associated with the failure of osseointegrated dental implants. It has 
been defined during the World Workshop on the Classification of 
Periodontal and Peri- implant Diseases and Conditions (June 2018, 
Chicago) as a plaque- associated pathological condition occurring in 
tissues around dental implants, characterized by inflammation in the 
peri- implant mucosa and loss of supporting bone (Berglundh et al., 
2018).
In the recent years, the role of antiresorptive/antiangiogenic 
drugs administration, and the subsequent possible occurrence of 
MRONJ, have been investigated as risk factors for implant failure. 
Because of MRONJ is often related to oral surgical procedures, such 
as dental extractions (Lam et al., 2007), the role of implant surgery 
as potential risk factor has been widely debated and there are sev-
eral guidelines, which remain still controversial (Campisi et al., 2020; 
Ruggiero et al., 2009); in the recent years, an increasing number 
of peri- implant MRONJ (PI- MRONJ) have been reported in liter-
ature both in oncologic and osteoporotic patients (Bedogni et al., 
2010; Favia et al., 2011; Kwon et al., 2012; Lazarovici et al., 2010). 
PI- MRONJ have been classified as implant surgery- triggered (onset 
within six months after implant placement and strictly related to the 
surgical procedure or a failure in osseointegration process) and non- 
implant surgery- triggered (onset more than six months after implant 
placement, or drug therapy started after implant placement and os-
seointegration) (Kwon et al., 2012).
The possible association between MRONJ and peri- implantitis 
has rarely been investigated in the current English literature 
(Troeltzsch et al., 2016). The clinico- radiological presence of peri- 
implantitis- like aspects in patients at risk of MRONJ development 
causes diagnostic problems between the diagnosis of simple peri- 
implantitis or that of PI- MRONJ.
The aim of this study is to report on the cases of 19 osteoporotic 
patients undergoing antiresorptive drugs with a previous diagnosis 
of peri- implantitis affected by PI- MRONJ, describing their salient 
clinical and histopathological features by using both conventional 
and confocal laser scanning microscopy (CLSM).
2  | MATERIAL S AND METHODS
This study was carried out in accordance with the principles of the 
Declaration of Helsinki and was approved by our Institutional Ethical 
Committee (study number 3,211, Prot. 201/C.E.- 30/01/2008); the 
patients released the informed consent on diagnostic and thera-
peutic procedures and possible use of the biological samples for re-
search purposes.
All the enrolled patients were sent to the Complex Operating 
Unit of Odontostomatology of Aldo Moro University of Bari from 
2010 to 2019 by their private dental practitioner, due to the pres-
ence of peri- implantitis not healed after non- surgical treatment. The 
inclusion criteria were as follows:
1. Patients affected by postmenopausal osteoporosis who were 
administered antiresorptive drugs;
2. Presence of osseointegrated dental implants placed successfully 
more than 6 months before the beginning of antiresorptive drugs 
administration;
3. Diagnosis of peri- implantitis around one or more dental implants, 
not healed after non- surgical peri- implant treatment.
During general anamnesis, the following clinical data were col-
lected: age, patient- related parameters (data on osteoporosis, pres-
ence of comorbidities), type, dose and duration of antiresorptive 
therapy, and information about dental implants (number, position, 
time of implant insertion, time between implant placement and an-
tiresorptive therapy).
All patients underwent the same diagnostic- therapeutic protocol 
consisting in:
• Clinical examination: evaluation of signs of peri- implantitis 
(Figure 1a,b) according with diagnostic criteria reported in The 
new classification of periodontal and peri- implant diseases and 
conditions— Consensus from world workshop in Chicago, June 2018 
(bleeding and/or suppuration on gentle probing; probing depths 
of >6 mm and bone levels >3 mm apical of the most coronal por-
tion of the intra- osseous part of the implant; bone loss beyond 
crestal bone- level changes resulting from initial bone remodelling)
• Radiological assessment: intraoral Rx, panoramic radiogram 
(Figure 1c) and multi- slices spiral computed tomography (CT) with 
three- dimensional reconstruction.
Considering the diagnosis of peri- implantitis for the patients 
treated before 2018, a reclassification of the peri- implant pathologic 
condition was performed by a retrospective analysis of periodontal 
charts saved in archives.
Then, considering the risk of MRONJ occurrence for these 
patients, in accordance with patients' general physicians, antire-
sorptive drugs administration was suspended and treatment of 
peri- implantitis was made at controlling infection by the elimi-
nation of the biofilm from the implant surface through a non- 
surgical approach. Implant fixtures were cleaned by instruments 
softer than titanium, such as plastic scaling instruments and ul-
trasonic scalers with a non- metallic tip. Submucosal treatment 
with diode laser and antimicrobial application (metronidazole 
40% gel) into peri- implant pocket was also performed. Before 
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each session, the persistence of peri- implantitis was defined by 
the evaluation of the probing depth values and presence of gin-
gival bleeding.
If signs of peri- implant pathologic condition did not heal after 
30 days and at least five sessions of such periodontal treatment, con-
sidering that peri- implantitis itself can be considered a risk factor for 
F I G U R E  1   Clinical and radiological images of a patient before and after surgery







habits Other comorbidities Other drugs
1 F 79 Risedronate 1 anterior lower jaw No Atrial fibrillation Anticoagulant
2 F 61 Alendronate 1 anterior upper jaw No Hypertension Beta- blockers
3 F 78 Denosumab 1 anterior lower jaw No Diabet Metformin
4 F 59 Denosumab 1 posterior lower jaw Yes None - 
5 F 62 Alendronate 1 anterior upper jaw No None - 
6 F 67 Risedronate 1 posterior lower jaw Yes Hypothyroidism Levothyroxine
7 F 54 Risedronate 1 anterior lower jaw Yes None - 
8 F 69 Denosumab 1 posterior lower jaw No None - 
9 F 56 Alendronate 2 anterior lower jaw No Gastroesophageal 
reflux disease
Pantoprazole
10 F 78 Alendronate 2 anterior upper jaw Yes Diabet Metformin
11 F 71 Clodronate 2 anterior lower jaw No None - 
12 F 62 Alendronate 2 posterior upper jaw Yes None - 
13 F 68 Denosumab 2 posterior lower jaw No Diabet Metformin
14 F 70 Ibandronate 2 anterior lower jaw No Hypothyroidism Levothyroxine
15 F 69 Clodronate 2 posterior upper jaw No None - 
16 F 67 Denosumab 3 anterior lower jaw Yes None - 
17 F 53 Ibandronate 3 posterior lower jaw Yes Hypertension Beta- blockers
18 F 57 Risedronate 2 posterior lower jaw No None - 
2 anterior lower jaw No
19 F 54 Alendronate 5 posterior+anterior 
upper jaw
No None - 
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MRONJ occurrence, surgical treatment was planned. Before the sur-
gical treatment, that cannot be performed less than 3 months after 
antiresorptive drugs discontinuation, combined antibiotic therapy 
(consisting of a combination of ceftriaxone 1 g via intra- muscle once 
a day and metronidazole 500 mg twice a day) for 8 days, repeated 
three times with a drug- free period of 10 days, was prescribed.
During surgery, first step consisted in removing implant fixtures 
with surrounding soft tissues; due to the presence of not vascular-
ized necrotic greenish osseous tissues, surrounding bone was also 
removed (Figure 1d) and bone core was performed for histopatho-
logical diagnosis. Then, osteoplasty with both rotative and piezosur-
gical devices of the residual resection margins was executed, and 
a medical device made of hyaluronic acid and amino acids (glycine, 
leucine, lysine and proline) was put into the bone defect to acceler-
ate the wound healing.
All the surgical samples were promptly fixed in 10% neutral 
buffered formalin and sent for the histopathological examination. 
Samples were decalcified in formic acid (5% in distilled water) for 
24 hr, embedded in paraffin, sectioned and stained with two dif-
ferent methods: haematoxylin– eosin for traditional microscopy and 
picrosirius red for CLSM. The histopathological analysis was per-
formed using Nikon Eclipse E600 microscope (Nikon Corporation), 
equipped with Argon- ion and Helio- Neon lasers (488 and 543 nm 
wavelengths, respectively), thus allowing both optical and confo-
cal laser scanning examination. The Nikon EZ C1 software (Nikon 
Corporation, ver. 2.10) was used for the bi- and tri- dimensional 
image processing.
Patients underwent clinical follow- up, respectively, after 2, 7, 15 
and 30 days, and panoramic radiogram was repeatedly performed 
once a month (Figure 1e,f).
3  | RESULTS
Overall, 19 female patients (average age 64.9 ± 8.3 y.o.,) were in-
cluded in the current study. They all had diagnosis of postmenopau-
sal osteoporosis treated with antiresorptive drugs.
Alendronate was administered to six of them, Denosumab to 
5, Risedronate to 4, Clodronate to 2 and Ibandronate to 2. Implant 
placement and duration of antiresorptive therapy were, respectively, 
on average of 45 months and 27 months before PI- MRONJ occur-
rence. Totally, patients showed 37 dental implants presenting signs 
of peri- implantitis; of them, 14 were placed on the anterior lower 
jaw, 10 on the posterior lower jaw, 7 on the posterior upper jaw and 
6 on the anterior upper jaw. Moreover, no signs of periodontitis or 
presence of bone exposure at other locations were evaluated. All 
patients’ data are reported in Table 1.
Considering signs of peri- implantitis, all implants showed bleed-
ing on probing and increasing probing depth (the average probing 
depth was 7 ± 1.2 mm), while suppuration was detected around 23 
implants, implant mobility was found in 13 cases. At radiological ex-
amination, the presence of bone defects typical of peri- implantitis 
was also evaluated.
After the conventional non- surgical treatment of peri- implantitis, 
although an improvement of signs was detected in some cases, no one 
case of complete healing was evaluated. For such reason, all patients 
underwent the surgical removal of implants and surrounding tissues. 
All treated lesions healed without signs of recurrence after a mean 
clinical and radiological follow- up of 20 months.
The conventional histopathological examination of the sur-
gical samples revealed the presence of large areas of bone re-
sorption at implant fixtures– bone interface (Figure 2), which 
certainly caused radiological radiolucency around implants, with 
areas of active acute and chronic phlogosis, characterized by 
polymorphonuclear phagocytes, plasma cells, monocytes and 
lymphocytes (Figure 3). Moreover, peculiar features of MRONJ 
were observed:
• irregular shaped and dilated Haversian channels filled of dense in-
flammatory infiltrate with prominent granulocytic cells, and with 
active resorption of the channel walls, and absence of vascular 
structures (Figure 2);
• presence of avascular bone necrosis in the bone surrounding the 
Haversian channels (Figure 2);
• macro- lamellar bone with large concentric hypercalcified oste-
onic structures, containing rare, clear and empty osteocytic lacu-
nae (osteocytic necrosis) (Figures 2 and 4);
• presence of basophilic bacterial colonies interspersed within 
the bony necrotic debris and the peri- implant soft tissues, 
and fulfilling the Haversian channels closed the implant site 
(Figure 3).
F I G U R E  2   Histopathological aspects of bone– implant fixtures 
interface
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At CLSM analysis with the 3D reconstruction with red fluo-
rescence (Figure 5), it underlined the intense internal osteoclastic 
resorption of the Haversian channels, showing multiple Howship's 
lacunae especially. So, the final diagnosis of peri- implantitis- like PI- 
MRONJ was made and, because implants were placed more than 
6 months before the beginning of the antiresorptive and/or antian-
giogenic treatment, all PI- MRONJ were classified as “non- surgery- 
triggered” and were considered spontaneous.
4  | DISCUSSION
After the first case described by Marx (Marx, 2003), cases of MRONJ 
have been reported increasingly and emerged as one of the major 
adverse side effects of antiresorptive and antiangiogenic therapy 
(Kwon et al., 2012). The pathogenesis seems to be related to a defect 
in jawbone physiologic remodelling, due to the strong inhibition of 
osteoclast activity with the following alteration of the normal bone 
turn over after surgical procedure or after local microdamage from 
the normal mechanical loading (Ruggiero & Drew, 2007; Santarelli 
et al., 2014). Recently, PI- MRONJ has been described (Kwon 
et al., 2012), but, to date, among all the procedures of oral and maxil-
lofacial surgery, it remains unclear if implant surgery represents a 
true risk factor for MRONJ development.
Some authors considered BPs treatment as an absolute contrain-
dication to oral implants, and more precisely both insertion of dental 
implants (implant surgery- triggered MRONJ) and the presence itself 
of a fixture (non- implant surgery- triggered MRONJ) represent a high 
risk factor for MRONJ occurrence, the latter appearing as a perma-
nent risk factor for the development MRONJ (Scully et al., 2006).
In contrast, other authors, such as Bell et al. Bell & Bell, (2008), 
Grant et al. Grant et al. (2008) and Koka et al. Koka et al. (2010), 
report on the lack of evidence of an increased risk of MRONJ in pa-
tients taking oral BPs and receiving dental implants, suggesting that 
implant therapy in BP users was a “safe and predictable procedure 
that did not require a drug holiday.”
On the contrary, in the same year, Goss et al. Goss et al. (2010) 
sustained that a “certain amount of risk” related to implant surgery 
for patients taking oral BPs exists, both for implant surgery- triggered 
and non- implant surgery- triggered MRONJ. Similar results have been 
reported by Jacobsen et al. Jacobsen et al. (2013); Bedogni et al. 
Bedogni et al. (2010) concluded that despite the low risk of MRONJ 
occurrence after implant surgery in oral BPs users, the success of 
dental implants remains uncertain. Therefore, all patients should be 
F I G U R E  3   Necrotic bone with bacterial colonies
F I G U R E  4   CLSM showed hypercalcified osteonic structures, 
with rare and empty osteocytic lacunae
F I G U R E  5   Internal osteoclastic resorption of Haversian 
channels at CLSM with 3D reconstruction
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accurately informed about the potential risk of implant failure and 
PI- MRONJ development both in the short and long term, and great 
attention should be paid to the long term maintenance of a good oral 
hygiene.
The few published histological studies on PI- MRONJ described 
three general patterns of bone involvement: (a) bone necrosis around 
the fixture, (b) extensive osteolysis around the fixture with or without 
sequestrum (peri- implantitis- like type) and (c) sequestration of bone 
with a preserved direct implant– bone contact (en- block type) (Kwon 
et al., 2012). In addition, these findings could also co- exist within the 
same lesion, the latter remaining strictly related to the severity both 
of bone destruction and infection associated (Favia et al., 2011).
The data available in the literature demonstrate that the oc-
currence of MRONJ in patients undergoing antiresorptive and an-
tiangiogenic therapy and needing implant- supported prosthetic 
rehabilitation or presenting dental implants is still an open and de-
bated question.
Considering non- surgery- triggered PI- MRONJ, the role of peri- 
implantitis as risk factor has been rarely investigated. Troeltzsch 
et al., Troeltzsch et al. (2016) in 2016, reported that signs of peri- 
implantitis appeared to be associated with the occurrence of PI- 
MRONJ in 39% of their case study, comprehending 117 dental 
implants in 34 patients.
In the current study, 19 patients were included. All of them were 
previously treated by their dental practitioner for peri- implantitis 
without healing of treated sites and, then, were sent to our attention. 
Considering patients’ anamnesis and previous administration of an-
tiresorptive drugs, we considered the hypothesis that peri- implantitis 
could be a sign of PI- MRONJ. Consequently, conventional treatment 
of peri- implantitis was performed again during antiresorptive drug 
suspension, and all not healed lesions were surgically treated.
Both conventional and CLSM histopathological analyses of surgi-
cal specimens highlighted that although peri- implant tissues showed 
bone resorption and inflammation typical of peri- implantitis, the 
surrounding bone was characterized by the histopathological fea-
tures of MRONJ (Favia et al., 2009), thus confirming the diagnosis of 
PI- MRONJ. Because implant placement was successfully performed 
more than 6 months before antiresorptive drugs administration, all 
PI- MRONJ were considered as spontaneous.
This data demonstrate that typical signs of peri- implantitis could 
be uncommon signs PI- MRONJ in patients taking antiresorptive/an-
tiangiogenic drugs, even if usual signs of MRONJ, as bone exposure 
or intra/extraoral fistula are not present. For such reasons, the dif-
ferential diagnosis between peri- implantits and PI- MRONJ is not al-
ways easy, thus producing delayed diagnosis. Consequently, it would 
be advisable to treat all peri- implantitis not healed after treatment 
as PI- MRONJ by surgical approach. Probably, the duration of drugs 
administration could be related to a higher onset of PI- MRONJ, thus 
considering that cellular bone turnover is progressively and increas-
ingly modified in close relationship to the duration of the therapy 
(Franco et al., 2014). Many other adjunctive factors should be con-
sidered in such patients, as the characteristics of the prosthetic 
rehabilitation, including the precision of implant- abutment and/or 
abutment- crown connection, could influence the functional loading 
and the maintenance of a good domestic oral hygiene. Moreover, it 
must not be underestimate the possibility that these cases of non- 
implant surgery- triggered PI- MRONJ, an initial peri- implantitis could 
be the local causing factor for ONJ occurrence, thus suggesting the 
importance of prevention of peri- implantitis in these patients.
On the basis of data reported in the international literature and in 
addiction of the results of the current study, the presence of dental 
implants should be always considered as an at- risk situation, there-
fore needing accurate attention and prevention. Peri- implantitis not 
healed after conventional non- surgical treatment in patients taking 
antiresorptive/antiangiogenic drugs has to be considered as peri- 
implantitis- like PI- MRONJ and treated as required in order to get 
complete healing of the pathological condition. So, according to au-
thor's experience, the removal of pathologic implants with surround-
ing bone is always mandatory in these patients considering the stage 
of PI- MRONJ diagnosed, as described in this study. Peri- implantitis 
itself could be the trigger factor for PI- MRONJ, so prevention is pri-
mary in these patients.
We retained that further review studies are needed to assess 
general guidelines for PI- MRONJ prevention, early diagnosis and 
management.
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